Docket No.: 20516 US/(C38435/111694)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

Tatsuo HOSHINO et al.

Serial No.: 09/727,855

Filed: December 1, 2000 Art Unit: 1674

For: PROCESS FOR THE MANUFACTURE

OF CAROTENOIDS AND BIOLOGICALLY USEFUL MATERIALS THEREOF

New York, NY October 18, 2001

# RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Box Sequence Commissioner for Patents Washington, DC 20231

Sir:

The two-months shortened statutory period of time for response to the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on August 23, 2001 ("Notice") expires on October 23, 2001. No fee is believed due at this time, however, if a fee is due, please charge any required fees to Deposit Account No. 02-4467. A duplicate of this sheet is enclosed.

In the Notice, the Examiner provided notification that the captioned application must be placed into compliance with the requirements of 37 CFR §§ 1.821 through 1.825. A copy of the Notice is attached as Exhibit A.

In response to the Notice, a paper copy and a computer readable format version of a Sequence Listing are submitted herewith, respectively, as Exhibits B and C.

#### **REMARKS**

Hard copy and computer readable versions of the Sequence Listing are submitted herewith. Pursuant to 37 CFR §1.821(f), undersigned counsel hereby represents that, upon information and belief, the content of the paper and computer readable Sequence Listings enclosed herewith are the same and that no new matter has been added.

It is believed that the Sequence Listing and computer readable form presented herewith place the captioned application into compliance with the requirements set forth in 37 CFR § 1.821. Entry of the Sequence Listing is respectfully solicited.

If the Examiner wishes to discuss any part of this submission, please contact the undersigned at the number indicated.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Box Sequence, Commissioner for Patents, Washington, DC 20231, on October 18, 2001.

Joy S. Goudie

Respectfully submitted,

Joy S. Goudie

Registration No. 48,146

BRYAN CAVE LLP

245 Park Avenue

New York, NY 10167-0034

Phone: (212) 692-1800 Fax: (212) 692-1900



### United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

ICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/727,855

12/01/2000

Tatsuo Hoshino

20516 US (C38435/111694)

CONFIRMATION NO. 4260

FORMALITIES LETTER

OC000000006462350\*

Mark E. Waddell, Esq. Bryan Cave LLP 245 Park Avenue New York, NY 10167-0034

Date Mailed: 08/23/2001

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

#### Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given TWO MONTHS from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
  - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE